Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Opinion
Video

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Recent Videos
Marion Munk, MD, PhD, presenting slides
Related Content
Adverum Biotechnologies shares positive 52-week LUNA and 4-year OPTIC results

Adverum Biotechnologies shares positive 52-week LUNA and 4-year OPTIC results

Sydney M Crago
November 21st 2024
Article
Opthea to present at upcoming events to highlight work on wet AMD

Opthea to present at upcoming events to highlight work on wet AMD

Sydney M Crago
November 21st 2024
Article
AlloVir, Inc. enters definitive merger agreement to combine with Kalaris Therapeutics

AlloVir, Inc. enters definitive merger agreement to combine with Kalaris Therapeutics

Sydney M Crago
November 18th 2024
Article
Wet AMD therapeutics: Technologies raising the ceiling for functional visual outcomes

Wet AMD therapeutics: Technologies raising the ceiling for functional visual outcomes

Sean D. Adrean, MD, FAAO
November 14th 2024
Article
FDA authorizes marketing of Valeda Light Delivery System for treatment of patients with dry AMD

FDA authorizes marketing of Valeda Light Delivery System for treatment of patients with dry AMD

Sydney M Crago
November 12th 2024
Article
FDA clears investigational new drug (IND) application for HG202 by HuidaGene Therapeutics

FDA clears investigational new drug (IND) application for HG202 by HuidaGene Therapeutics

Sydney M Crago
November 12th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.